Novel Antigen for Immunization in Cancer
- Detailed Technology Description
- Experiments have also been conducted using transgenic mice engineered to mimic the human immune system. The prototype telomerase vaccine induced a CTL response in these mice with no apparent negative side effects, demonstrating the potential of this vaccine in an animal model. Since telomerase is essential in the normal process of cell division, autoimmune reactions are a concern for this type of vaccine. However, in addition to the lack of side effects observed in the mouse model, tests of the vaccine on normal human stem cells, which have higher levels of telomerase than other normal cells, showed no adverse effects.
- Supplementary Information
- Patent Number: US7388071B2
Application Number: US2001788110A
Inventor: Zanetti, Maurizio
Priority Date: 15 Feb 2000
Priority Number: US7388071B2
Application Date: 15 Feb 2001
Publication Date: 17 Jun 2008
IPC Current: A61K003800 | A01N003718 | A61K003514 | A61K003900 | A61P003500 | C07K000706 | C07K000708
US Class: 530300 | 530328 | 514002 | 514015 | 514021
Assignee Applicant: The Regents of the University of California
Title: Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
Usefulness: Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
Summary: The vaccine is useful for treating cancer or tumors, for targeting cytotoxic T lymphocytes to tumor cells, and for inducing or augmenting a cancer patient's immune response against tumor (claimed).
Novelty: Vaccine for initiating and enhancing a cytotoxic T lymphocyte response, for treating cancers or tumors or for inducing immune response against tumors, comprises a telomerase reverse transcriptase peptide
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Application No.
- 7388071
- Others
-
State Of Development
This technology is available for licensing. See U.S. patent number 7,338,071 issued on 06/17/08 “Composition and Methods for Inducing and Enhancing a Telomerase Reverse Transcriptase—Reactive Cytotoxic T Lymphocyte Response.” Also see the continuing application, U.S. Publication Number US2009/0074741.
Tech ID/UC Case
19221/2000-051-0
Related Cases
2000-051-0
- *Abstract
-
Vaccination against an enzyme common to a variety of human tumors might effectively mobilize the body’s own immune system to attack and kill cancer cells. Telomerase, an enzyme involved in maintaining normal chromosome length during replication and key to the uncontrolled replication of cancerous cells, is considered to play a direct role in tumor transformation by allowing the immortalization of precancerous cells.
A prototype vaccine made from peptides of telomerase reverse transcriptase (hTRT) has been devised that can activate cytotoxic T-lymphocytes (CTL) in vitro. Lymphocytes from prostate cancer patients were readily activated into CTL following immunization with the prototype vaccine, leading to destruction of the cancer cells. CTL produced in prostate cancer cells were also effective in targeting hTPT peptides in other human cancer cells such as breast, colon, lung, and melanoma and in attacking and killing these cancer cells.
- *IP Issue Date
- Jun 17, 2008
- *Principal Investigator
-
Name: Maurizio Zanetti
Department:
- Country/Region
- USA
